Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)-Reference-Cited by-同舟云学术

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

Published:2018-04-29 Issue:12 Volume:78 Page:889-895
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Francini Edoardo¹²^ORCID,Gray Kathryn P.¹,Xie Wanling¹,Shaw Grace K.¹,Valença Loana³,Bernard Brandon⁴,Albiges Laurence⁵,Harshman Lauren C.¹^ORCID,Kantoff Philip W.⁶,Taplin Mary-Ellen¹,Sweeney Cristopher J.¹

Affiliation:

1. Dana-Farber Cancer Institute; Lank Center for Genitourinary Oncology; Boston Massachusetts

2. Sapienza University of Rome; Rome Italy

3. Hospital Santa Izabel; Salvador Bahia Brazil

4. University of Colorado Cancer Center; Aurora Colorado

5. Institut Gustave Roussy; Villejuif France

6. Memorial Sloan Kettering Cancer Center; New York New York

Publisher

Wiley

Subject

Urology,Oncology

Reference21 articles.

1. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland;Huggins;Arch Surg,1941

2. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346);Tangen;J Urol,2012

3. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion;Harris;Nat Pract Urol,2009

4. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches;Karantanos;Oncogene,2013

5. Correlation between clinical response to hormone therapy and steroid receptor content in prostatic cancer;Gustafsson;Cancer Res,1978

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale;Clinical Genitourinary Cancer;2024-12

2. Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer;Urologic Oncology: Seminars and Original Investigations;2024-11

3. Influence of Tumor Characteristics and Time to Metastatic Disease on Oncological Outcomes in Metachronous Metastatic Prostate Cancer Patients;Clinical Genitourinary Cancer;2024-10

4. Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy;The Prostate;2024-09-06

5. Metastatic hormone-naïve prostate cancer: a distinct biological entity;Trends in Cancer;2024-09